SCHEMBL160262

SCHEMBL160262

FC(F)(F)c1ccc[c]c1Cl

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.36
ALDH1A1 P00352 2/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NOTUM Q6P988 3/20 0.33
HSD11B1 P28845 1/20 0.32
KDM4E B2RXH2 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD17B10 Q99714 1/20 0.32
IDO1 P14902 2/20 0.31
CA2 P00918 1/20 0.31
AR P10275 2/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3416823 0.82 HSD11B1 (0.41) ALDH1A1NOTUMHSD11B1HSD17B10AR
SCHEMBL21354744 0.79 CYP3A4 (0.33) TDP1
SCHEMBL24092 0.77 CA2 (0.39) ALDH1A1TDP1CA2
SCHEMBL13728893 0.77 HSD11B1 (0.37) P2RX7NOTUMHSD11B1AR
SCHEMBL6513958 0.77 ACHE (0.35) ALDH1A1POLBKDM4EHSD17B10LMNA
SCHEMBL20955825 0.76
SCHEMBL82438 0.74 TDP1 (0.34) ALDH1A1POLBTDP1L3MBTL1NOTUM
SCHEMBL81363 0.74 ALDH1A1 (0.39) ALDH1A1POLBTDP1L3MBTL1HSD11B1
SCHEMBL13730506 0.73 AR (0.46) NOTUMIDO1AR
SCHEMBL13730818 0.73 HSD11B1 (0.39) TDP1HSD11B1KDM4EAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110770214-B Heterocyclic P2X7 antagonists 布雷耶疗法有限公司 2024-03-29 CN claimed
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION FIBROGEN, INC. 2024-01-04 US claimed
WO-2023239768-A1 TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS INCYTE CORPORATION (US) 2023-12-14 WO claimed
US-20230399342-A1 TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS INCYTE CORPORATION 2023-12-14 US claimed
EP-4204400-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION Fibrogen, Inc. (US) 2023-07-05 EP claimed
CN-110536892-B Novel bicyclic pyrazole derivatives 拜耳动物保健有限责任公司 2023-05-12 CN claimed
US-11623919-B2 Heterocyclic P2X7 antagonists BREYE THERAPEUTICS APS (DK) 2023-04-11 US claimed
CN-110003200-B P2X7 modulators 詹森药业有限公司 2021-11-26 CN claimed
US-11130768-B2 Bicyclic pyrazole derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-09-28 US claimed
EP-3091970-B1 LXR AGONISTS AND USES THEREOF RGENIX INC (US) 2020-10-28 EP claimed
US-4540429-A 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders STAUFFER CHEMICAL COMPANY (US) 1985-09-10 US claimed
US-4512989-A IMIDOESTERS OR IMIDOTHIOESTERS HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 1985-04-23 US claimed
EP-0062773-B1 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders STAUFFER CHEMICAL COMPANY (US) 1984-12-05 EP claimed
EP-0125803-A2 Pharmaceutically active dihydropyridines FISONS plc (GB) 1984-11-21 EP claimed
EP-0118864-A1 Pyrimidinyl derivatives BAYER AG (DE) 1984-09-19 EP claimed
EP-0116769-A1 Dihydropyridines Pfizer Limited (GB) 1984-08-29 EP claimed
US-4391804-A Imidazole derivatives and fungicidal composition containing the same HOKKO CHEMICAL INDUSTRY COMPANY, LTD. (JP) 1983-07-05 US claimed
EP-0062773-A1 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders STAUFFER CHEMICAL COMPANY (US) 1982-10-20 EP claimed
US-4146386-A Phthalic dianilides and their use as plant growth regulators MONSANTO COMPANY (US) 1979-03-27 US claimed
US-4016281-A Tetralone and indanone compounds MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-04-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11623919-B2 Heterocyclic P2X7 antagonists P2RY1, P2RX1, P2RX3 P2RX7 4/4885ALDH1A1 1689/4885POLB 4137/4885
US-11130768-B2 Bicyclic pyrazole derivatives CYP1B1, CYP3A43, CYP3A5 P2RX7 82/4885ALDH1A1 805/4885POLB 2003/4885
US-20230399342-A1 TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS DGKA, DGKI, DGKG P2RX7 2750/4885ALDH1A1 4279/4885POLB 2276/4885
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION KDM5C, KDM5B, KDM5A P2RX7 4287/4885ALDH1A1 2449/4885POLB 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.